Drug intelligence / Profile preview

AIG-Onco3

Development stage: Discontinued
Lead developer: AIGEN Sciences
Modality: Small Molecules

Overview

AIG-Onco3 is a small molecule drug candidate that was developed by Aigen Sciences for the treatment of neoplasms, specifically targeting solid tumors. The drug reached the discovery phase in development and did not advance to clinical trials. Its mechanism of action, molecular target(s), and detailed pharmacological profile have not been publicly disclosed. As of March 2025, development of AIG-Onco3 has been discontinued.

Beyond the preview

Go deeper on AIG-Onco3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIG-Onco3.

Explore the full profile